Moderna Shares Rally 19.6% Monthly, Prepare for Q4 EPS of -$2.60
Moderna shares jumped 2.29% to $41.95 after a 19.56% monthly gain outpacing the Medical sector’s 2.92% and S&P’s 0.16% decline. Analysts forecast Q4 EPS of -$2.60 on $661.4 million revenue, down 31.5% year-over-year, with full-year revenue eyed at $1.88 billion.
1. Recent Stock Performance
Moderna closed at $41.95 on February 9, rising 2.29% versus a 0.47% gain for the S&P 500, 0.04% for the Dow and 0.9% for the Nasdaq in the same session.
2. Monthly Outperformance
Over the past month, Moderna shares have climbed 19.56%, vastly outperforming the Medical sector’s 2.92% gain and the S&P 500’s 0.16% loss.
3. Q4 Earnings Outlook
The company is set to report Q4 results on February 13, with analysts projecting EPS of -$2.60 and revenue of $661.4 million, representing a 31.5% decline in sales versus the year-ago quarter.
4. Full-Year Forecast and Analyst Ratings
Full-year consensus calls for EPS of -$7.81 (an 11.95% improvement) on $1.88 billion revenue (down 41.83%), while analyst EPS estimates have risen 2.48% this month and the stock holds a Hold rating; its biomedical and genetics industry ranks in the top 37% of over 250 industries.